Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trial on the Safety and Efficacy of Neoantigen Antigen mRNA Tumor Vaccine in the Treatment of Advanced Esophageal Cancer and Non-small Cell Lung Cancer

Next Previous
Trial Profile

Clinical Trial on the Safety and Efficacy of Neoantigen Antigen mRNA Tumor Vaccine in the Treatment of Advanced Esophageal Cancer and Non-small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SW 1115C3 (Primary)
  • Indications Non-small cell lung cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Stemirna Therapeutics

Most Recent Events

  • 11 Apr 2023 Planned End Date changed from 1 Sep 2022 to 31 Dec 2025.
  • 11 Apr 2023 Planned primary completion date changed from 1 Sep 2020 to 31 Oct 2024.
  • 11 Apr 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top